Cell Reports
Volume 38, Issue 10, 8 March 2022, 110502
Journal home page for Cell Reports

Report
BCG vaccination provides protection against IAV but not SARS-CoV-2

https://doi.org/10.1016/j.celrep.2022.110502Get rights and content
Under a Creative Commons license
open access

Highlights

  • BCG vaccination provides significant protection against IAV in mice and hamsters

  • BCG provides no protection against SARS-CoV-2 in mice and hamsters

  • SARS-CoV-2 induces pulmonary hemorrhage and disseminates to the bone marrow

  • Monocytes from BCG-vaccinated humans induce more cytokines to IAV than SARS-CoV-2

Summary

Since the vast majority of species solely rely on innate immunity for host defense, it stands to reason that a critical evolutionary trait like immunological memory evolved in this primitive branch of our immune system. There is ample evidence that vaccines such as bacillus Calmette-Guérin (BCG) induce protective innate immune memory responses (trained immunity) against heterologous pathogens. Here we show that while BCG vaccination significantly reduces morbidity and mortality against influenza A virus (IAV), it fails to provide protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In contrast to IAV, SARS-CoV-2 infection leads to unique pulmonary vasculature damage facilitating viral dissemination to other organs, including the bone marrow (BM), a central site for BCG-mediated trained immunity. Finally, monocytes from BCG-vaccinated individuals mount an efficient cytokine response to IAV infection, while this response is minimal following SARS-CoV-2. Collectively, our data suggest that the protective capacity of BCG vaccination is contingent on viral pathogenesis and tissue tropism.

Keywords

SARS-CoV-2
influenza virus
BCG vaccination
animal models
trained immunity
hematopoietic stem cells
lung pathology
monocytes

Cited by (0)

10

These authors contributed equally

11

Lead contact